Translating Research Into Practice
Assessment of Pathologic Response in Patients With Locally Advanced Rectal Cancer: Implications of the Park et al. Study
Annie R. Truong, PA-C, and Steven H. Wei, MS, MPH, PA-C
From MD Anderson Cancer Center, Houston, Texas
The authors have no conflicts of interest to disclose.
Correspondence to: Steven H. Wei, MS, MPH, PA-C, MD Anderson Cancer Center, Surgical Oncology, 1400 Pressler Street, Houston, TX 77030. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2013;4:445–450 |
DOI: 10.6004/jadpro.2013.4.6.7 |
© 2013 Harborside Press®
In a recent article in the Journal of Clinical Oncology, Park and colleagues reported on neoadjuvant treatment response as an early indicator of response for patients with rectal cancer. In this pair of articles, JADPRO contributors discuss the implications of this study in terms of how assessment of response after neoadjuvant chemoradiotherapy impacts further management of the disease.
For access to the full length article, please sign in